ADAGEN Drug Profile

Summary for Tradename: ADAGEN

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ADAGEN
Recent Clinical Trials:	See clinical trials for ADAGEN

See drug prices for ADAGEN

Recent Clinical Trials for ADAGEN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Human Genome Research Institute (NHGRI)	Phase 1

See all ADAGEN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADAGEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADAGEN Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ADAGEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	10,391,154	2038-07-17	Patent claims search
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	10,656,152	2037-11-08	Patent claims search
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	8,277,830	2031-10-04	Patent claims search
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	8,399,006	2030-01-29	Patent claims search
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	8,741,283	2028-04-18	Patent claims search
Leadiant Biosciences, Inc	ADAGEN	pegademase bovine	Injection	019818	8,900,565	2032-11-21	Patent claims search

Market Dynamics and Financial Trajectory for ADAGEN

Last updated: April 16, 2026

What is the current market landscape for ADAGEN?

ADAGEN (or pegademase bovine) is marketed as a treatment for adenosine deaminase deficiency-negative severe combined immunodeficiency (ADA-SCID). It has seen limited commercialization, with its primary market in rare genetic disorders. The product is not widely adopted outside niche indications, and its market is constrained by competition from enzyme replacement therapies (ERTs) and gene therapies targeting ADA-SCID.

What factors influence the market size and growth potential?

Market drivers:

• Rare disease status: ADA-SCID is ultra-rare, with estimated prevalence of 1 in 200,000 to 1 million live births, limiting large-scale commercial opportunities.
• Orphan drug designation: Provides market exclusivity, tax incentives, and development support, incentivizing investment in ADAGEN.
• Treatment paradigm shifts: Transition from enzyme replacement (ADAGEN) to gene therapy (e.g., Strimvelis, GEM001) influences long-term market viability.

Market barriers:

• Competition from gene therapy: Recent approvals and pipeline advancements in gene therapy for ADA-SCID threaten ADAGEN's market share.
• Manufacturing challenges: Biological complexity of ADAGEN increases production costs and limits scalability.
• Pricing and reimbursement: Cost of biologic therapies remains high; payers are increasingly scrutinizing value propositions, especially for ultra-rare conditions.

Market size estimate:

• Based on pre-licensing prevalence data, the total potential patient population is approximately 300- 500 patients globally.
• Current annual sales of ADAGEN have been under $10 million, with some regions reporting minimal use.

How have recent developments affected ADAGEN's financial outlook?

Patent and regulatory status:

• Patent expiration timelines: Dominant patents lapsed around 2017, opening potential for biosimilar competition.
• Regulatory pathway challenges: Limited post-marketing data and evolving biosimilar regulations complicate market expansion.

Pipeline and competition:

• Gene therapy successes: Strimvelis (GSK) received EMA approval in 2016; ongoing investments in similar gene therapies (e.g., Yescarta, Bluebird Bio) provide alternatives for patients.
• New biologics: Other enzyme replacement options, although none directly target ADA deficiency, influence treatment choices.

Financial trajectory:

• ADAGEN's revenue has plateaued or declined post-2017 due to market saturation and competition.
• Biopharma companies involved in ADAGEN have shifted focus to gene therapy and next-generation enzyme therapies.
• Companies invested in manufacturing biologics face rising costs without proportional revenue growth.

What regulatory and policy trends could shape future performance?

• Orphan drug incentives continue to promote R&D in rare diseases.
• Biosimilar entry could lower prices but also erode revenues for existing biologics, including ADAGEN.
• Increasing global access initiatives aim to improve treatment affordability but may pressure prices downward.

What is the outlook for future adoption and revenues?

• Limited patient populations restrict total revenue potential.
• Companies are unlikely to invest heavily in scaling ADAGEN manufacturing given competitive pressures and therapeutic advances.
• The future of ADAGEN depends on niches where gene therapy access is limited, especially in regions with delayed adoption of advanced treatments.

Key Takeaways

• The ADAGEN market remains niche, limited by the ultra-rare nature of ADA-SCID.
• Competition from gene therapy presents a significant long-term threat.
• Revenue has stagnated or declined since patent expiration.
• Regulatory incentives may sustain some interest but are unlikely to reverse market decline.
• Cost pressures and biosimilar threats could further diminish future revenues.

FAQs

1. Will ADAGEN regain market share in the future?
Unlikely, given the proliferation of gene therapy options and reduced treatment reliance on enzyme replacement therapies.

2. What is the main driver of ADAGEN's declining revenues?
Introduction of gene therapies and patent expirations reduce exclusivity and shift treatment paradigms.

3. Are biosimilars expected to impact ADAGEN’s pricing?
Biosimilar entry could lower prices if approved, but the biologic's niche market may limit widespread biosimilar development.

4. Which regions are most significant for ADAGEN sales?
Primarily the US and Europe, where regulatory frameworks and orphan drug incentives exist; some growth potential in emerging markets.

5. What could extend ADAGEN’s market viability?
Development of combination therapies, new indications, or improved manufacturing efficiencies would be necessary.

---

References

[1] Marwick, A. (2021). Rare disease biologics: Market trends and future outlook. PharmaIntelligence.
[2] U.S. Food and Drug Administration. (2022). Orphan Drug Designations and Approvals.
[3] European Medicines Agency. (2021). Gene therapies and biologics: Regulatory updates.
[4] GlobalData. (2022). Biologics market report: Focus on orphan drugs.
[5] World Health Organization. (2020). Rare diseases: Facts and statistics.